Abstract：
:Epithelial ovarian cancer (EOC) is the most common gynaecological malignancy in the Western world and a leading cause of death. Patients with relapsed EOC are incurable and therefore the toxicity of palliative chemotherapy and effects on health-related Quality of Life are important factors. Several newer cytotoxic agents have been used in these patients. Pegylated liposomal doxorubicin (Caelyx) has a different spectrum of activity from standard doxorubicin with response rates up to 25% in these patients and a low toxicity profile. In addition it is non cross resistant with platinum compounds. In a randomised phase III trial (n=474) of Caelyx versus Topotecan there were no significant differences in response rates, time to progression, overall survival or quality of life. Patients receiving Topotecan had more side effects requiring admission to hospital. Caelyx is a valuable therapy in platinum resistant patients with an efficacy equivalent to Topotecan but at a lower cost when side-effects and admission costs are included.
journal_name
Cancer Treat Revjournal_title
Cancer treatment reviewsauthors
Stebbing J,Gaya Adoi
10.1053/ctrv.2002.0262keywords:
subject
Has Abstractpub_date
2002-04-01 00:00:00pages
121-5issue
2eissn
0305-7372issn
1532-1967pii
S0305737202902628journal_volume
28pub_type
临床试验,杂志文章,随机对照试验,评审abstract：:Breast cancer is the most common malignancy in women worldwide, with a relatively high proportion of patients experiencing resistance to standard treatments. Cellular immunotherapy (CI), which is based on the extraction, modification, and re-infusion of the patient's immune cells, is showing promising results in these...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2020.102089
更新日期：2020-11-01 00:00:00
abstract：:Aflibercept, also known as vascular endothelial growth factor (VEGF)-Trap, is a recombinant, decoy receptor fusion protein, rationally designed to block angiogenesis by targeting not only all forms of VEGF-A, but also VEGF-B and placental growth factor. It inhibits VEGF-induced angiogenesis in preclinical models. In t...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2011.12.008
更新日期：2012-08-01 00:00:00
abstract：:Arc therapies have gained widespread clinical interest in radiation oncology over the past decade. Arc therapies have several potential advantages over standard techniques such as intensity-modulated radiation therapy, with implications for patients, administrators, and oncologists. This review focuses on the rational...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2010.01.004
更新日期：2010-08-01 00:00:00
abstract：:The role of adjuvant chemotherapy in patients with stage III colon cancer is now well established and 5-FU/LV should be the reference regimen to which new drugs are tested against in the adjuvant setting. In stage II colon cancer, because the risk of recurrence is lower, any absolute benefit of chemotherapy is likely ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/s0305-7372(02)00047-6
更新日期：2002-10-01 00:00:00
abstract：:Ilmofosine is a cytostatic/cytotoxic thioether phospholipid derivative. The in vivo anti-tumour activity of this compound was investigated in a methylcholanthrene (MethA)-induced fibrosarcoma and in the 3Lewis-lung carcinoma systems, respectively. Ilmofosine showed antineoplastic and antimetastatic properties at oral ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章
doi：10.1016/0305-7372(90)90055-k
更新日期：1990-09-01 00:00:00
abstract：:Metastatic colorectal cancer remains a public-health issue on a global scale. With development of a new generation of cytotoxic agents, survival has improved for patients with metastatic disease. How to maximize the benefit of chemotherapy with acceptable toxicity remains incompletely answered. Hepatic resection can p...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2006.07.005
更新日期：2006-11-01 00:00:00
abstract：:Neuroendocrine neoplasms are a low-incidence and heterogeneous group of malignancies. In the advanced stage, several therapeutic options can be discussed, including molecular-targeted agents, but biological predicting factors are lacking. A number of molecular targets have been studied over the last decade leading to ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2014.06.009
更新日期：2014-09-01 00:00:00
abstract：:Malignant Pleural Mesothelioma (MPM) is an aggressive tumour with poor prognosis and increasing incidence in industrialized countries because of the previous widespread exposure to asbestos fibres and to the long lag period from time of exposure and the diagnosis of the disease. MPM shows high refractoriety to systemi...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2012.03.001
更新日期：2013-02-01 00:00:00
abstract：:TP53 (p53) is the most frequently mutated gene in cancer, being altered in approximately 50% of human malignancies. In most, if not all, cancers lacking mutation, wild-type (WT) p53 is inactivated by interaction with cellular (MDM2/MDM4) or viral proteins, leading to its degradation. Because of its near universal alte...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2014.10.004
更新日期：2014-12-01 00:00:00
abstract：:The present study describes a female child, who had a primary defect in the ability of her T-cells to secrete interleukin-2. Numbers of B- and T-cells were normal, but their functions were severely deficient. The patient had decreased immunoglobulins and poor ability to mount antibody responses. Phytohemagglutinin (PH...
journal_title：Cancer treatment reviews
pub_type： 杂志文章
doi：10.1016/0305-7372(89)90034-0
更新日期：1989-06-01 00:00:00
abstract：:Targeted therapies have unique toxicity profiles. Common adverse events include rash, diarrhea, hypertension, hypothyroidism, proteinuria, depigmentation, and hepatotoxicity. Some of these toxicities are caused by on-target, mechanism-associated effects, which can be stratified as to whether or not the targets are rel...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2014.05.003
更新日期：2014-08-01 00:00:00
abstract：:The majority of stage III NSCLC patients managed with a combination of radiotherapy and chemotherapy will develop a locoregional or distant relapse. Concomitant radiochemotherapy allows for improved local control but has no impact on extrathoracic recurrences. To ameliorate this inefficiency the concept of consolidati...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2018.04.001
更新日期：2018-05-01 00:00:00
abstract：:Standard first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) is docetaxel plus prednisone; however, patients will usually experience disease progression during or after docetaxel treatment due to inherent or acquired resistance. Before 2010, second-line options for mCRPC were limited. Howe...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2013.06.008
更新日期：2014-02-01 00:00:00
abstract：:Bone-seeking radionuclides, such as Sr-89, Sm-153, and Re-186, have been shown to have an effect on pain from bone metastasis in prostate cancer. The effect on bone pain in other cancer types, including breast cancer, remains unclear. The purpose of the study was to perform a systematic review of the use of radioisoto...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,随机对照试验,评审
doi：10.1016/j.ctrv.2011.05.008
更新日期：2012-04-01 00:00:00
abstract：:RAS family proteins (including KRAS and NRAS) play important roles in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci in exons 2, 3, and 4) often result in constitutive activation of RAS proteins and persistent downstream signaling. Mutations in KRAS exon 2 (cod...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2015.05.008
更新日期：2015-09-01 00:00:00
abstract：:The prognosis of advanced pancreatic adenocarcinoma is still poor nowadays. Gemcitabine in monotherapy (30-min infusion) has been the standard of treatment during the last decade, and many clinical trials have failed to demonstrate an improvement in overall survival (OS) with the addition of different drugs to gemcita...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2008.11.007
更新日期：2009-06-01 00:00:00
abstract：:Non-small cell lung cancer (NSCLC) accounts for >80% of lung cancer cases and currently has an overall five-year survival rate of only 15%. Patients presenting with advanced stage NSCLC die within 18-months of diagnosis. Metastatic spread accounts for >70% of these deaths. Thus elucidation of the mechanistic basis of ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2013.10.001
更新日期：2014-05-01 00:00:00
abstract：:Patients with solid tumours are at risk of impaired bone health from metastases and cancer therapy-induced bone loss (CTIBL). We review medical management of bone health in patients with solid tumours over the past 30 years, from first-generation bisphosphonates to the receptor activator of nuclear factor κB ligand (R...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2019.05.003
更新日期：2019-06-01 00:00:00
abstract：:Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene express...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2016.08.004
更新日期：2016-11-01 00:00:00
abstract：:Neoadjuvant chemotherapy (NAC) for breast cancer is evolving and subsequent adjuvant systemic treatment is mainly based on the presence of the Estrogen (ER) receptor, Progesterone (PR) receptor and Human Epidermal growth factor Receptor 2 (HER2) status on the core needle biopsy prior to treatment. It is not well known...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2010.11.006
更新日期：2011-10-01 00:00:00
abstract：:Prostate cancer is the most common cancer in men. Overall survival is considered the best endpoint for clinical trials, but it is difficult to use in phase-2 studies. Although the reduction of PSA after cytotoxic chemotherapy has been identified as a valid surrogate for overall survival, it has not proven reliable for...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2012.03.008
更新日期：2012-12-01 00:00:00
abstract：:Adolescent patients with cancer reside in a "no-man's land" between the world of pediatric oncology and that of "adult" medical oncology. As compared to younger and older patients, adolescents and young adults are under-represented on clinical trials. This relative lack of participation in clinical protocols has been ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2006.11.005
更新日期：2007-11-01 00:00:00
abstract：:Given its role in cellular metabolism, the proteasome could prove to be a critical target that can be exploited in treating cancer. In preclinical studies, several mechanisms for bortezomib's activity in multiple myeloma cells have been identified (e.g., NF-kappaB inhibition); antitumor activity with bortezomib has be...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/s0305-7372(03)00079-3
更新日期：2003-05-01 00:00:00
abstract：:The N-methyl-N'-nitroso-guanidine human osteosarcoma transforming gene (MET) receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) control cellular signaling cascades that direct cell growth, proliferation, survival, and motility. Aberrant MET/HGF activation has been observed in many tumor types, can ...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,meta分析,评审
doi：10.1016/j.ctrv.2013.02.001
更新日期：2013-11-01 00:00:00
abstract：BACKGROUND:Epidemiological evidence supports the existence of a survival advantage for female patients with melanoma. This survival advantage often persists when other prognostic variables are taken into account. The basis for this female advantage or male disadvantage is not established although female sex steroids ca...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1053/ctrv.2001.0220
更新日期：2001-08-01 00:00:00
abstract：:While chemotherapy has been the standard of care for patients with advanced non-small cell lung cancer (NSCLC), efforts have shifted toward evaluating novel targeted agents in an attempt to improve outcome. These targeted agents are directed toward key components in several signalling pathways such as vascular endothe...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2011.05.009
更新日期：2012-05-01 00:00:00
abstract：:Low Grade Serous Ovarian Carcinoma, LGSOC, is certainly a rare disease, accounting for only a small proportion of all ovarian carcinomas, nevertheless in the last decade we have acquired many data about its molecular and clinical features and it has been largely accepted that it has distinct pathogenesis, genetic aber...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2014.12.003
更新日期：2015-02-01 00:00:00
abstract：:The chemo-immunotherapy (CIT) and chemo-adoptive immunotherapy (CAIT) regimens tested in the past decade are summarized. From them we have learned a great deal about the interactions between various chemotherapeutic agents, immune modulating agents and effector cells. The most commonly reported result in multi-modalit...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1053/ctrv.2001.0222
更新日期：2001-12-01 00:00:00
abstract：:Hyperprogressive disease (HPD) is a concerning paradoxical acceleration of cancer growth induced by immune drugs. The lack of standard radiological criteria makes its study challenging. We reviewed the literature and compared the main criteria for HPD proposed by Ferté, Le Tourneau, Garralda and Caramella to address t...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2020.102116
更新日期：2020-12-01 00:00:00
abstract：:Pancreatic cancer is a disease with a high mortality rate and short survival, as a result of the high incidence of metastatic disease at diagnosis, the fulminant clinical course and the lack of successful therapeutic strategies. The administration of chemotherapeutic agents for the treatment of advanced disease has fa...
journal_title：Cancer treatment reviews
pub_type： 杂志文章,评审
doi：10.1016/j.ctrv.2009.02.005
更新日期：2009-08-01 00:00:00
